328 related articles for article (PubMed ID: 29719442)
1. Ataxia-telangiectasia gene (
Jerzak KJ; Mancuso T; Eisen A
Curr Oncol; 2018 Apr; 25(2):e176-e180. PubMed ID: 29719442
[TBL] [Abstract][Full Text] [Related]
2. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline.
van Os NJ; Roeleveld N; Weemaes CM; Jongmans MC; Janssens GO; Taylor AM; Hoogerbrugge N; Willemsen MA
Clin Genet; 2016 Aug; 90(2):105-17. PubMed ID: 26662178
[TBL] [Abstract][Full Text] [Related]
3. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
Weidner AE; Liggin ME; Zuniga BI; Tezak AL; Wiesner GL; Pal T
Cancer; 2020 Apr; 126(8):1651-1655. PubMed ID: 31967672
[TBL] [Abstract][Full Text] [Related]
5. Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.
Lowry KP; Geuzinge HA; Stout NK; Alagoz O; Hampton J; Kerlikowske K; de Koning HJ; Miglioretti DL; van Ravesteyn NT; Schechter C; Sprague BL; Tosteson ANA; Trentham-Dietz A; Weaver D; Yaffe MJ; Yeh JM; Couch FJ; Hu C; Kraft P; Polley EC; Mandelblatt JS; Kurian AW; Robson ME;
JAMA Oncol; 2022 Apr; 8(4):587-596. PubMed ID: 35175286
[TBL] [Abstract][Full Text] [Related]
6. ATM mutations for surgeons.
Mansfield SA; Pilarski R; Agnese DM
Fam Cancer; 2017 Jul; 16(3):407-410. PubMed ID: 27988859
[TBL] [Abstract][Full Text] [Related]
7. ATM Variants in Breast Cancer: Implications for Breast Radiation Therapy Treatment Recommendations.
McDuff SGR; Bellon JR; Shannon KM; Gadd MA; Dunn S; Rosenstein BS; Ho AY
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1373-1382. PubMed ID: 33545302
[TBL] [Abstract][Full Text] [Related]
8. Diversity of ATM gene variants: a population-based genome data analysis for precision medicine.
Fukunaga H; Taki Y; Prise KM
Hum Genomics; 2019 Aug; 13(1):38. PubMed ID: 31443742
[TBL] [Abstract][Full Text] [Related]
9. ATM, radiation, and the risk of second primary breast cancer.
Bernstein JL; ; Concannon P
Int J Radiat Biol; 2017 Oct; 93(10):1121-1127. PubMed ID: 28627265
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Breast Cancer Risk Assessment for
Gallagher S; Hughes E; Kurian AW; Domchek SM; Garber J; Probst B; Morris B; Tshiaba P; Meek S; Rosenthal E; Roa B; Slavin TP; Wagner S; Weitzel J; Gutin A; Lanchbury JS; Robson M
JCO Precis Oncol; 2021 Jun; 5():. PubMed ID: 34322652
[TBL] [Abstract][Full Text] [Related]
11. Telomere length, ATM mutation status and cancer risk in Ataxia-Telangiectasia families.
Renault AL; Mebirouk N; Cavaciuti E; Le Gal D; Lecarpentier J; d'Enghien CD; Laugé A; Dondon MG; Labbé M; Lesca G; Leroux D; Gladieff L; Adenis C; Faivre L; Gilbert-Dussardier B; Lortholary A; Fricker JP; Dahan K; Bay JO; Longy M; Buecher B; Janin N; Zattara H; Berthet P; Combès A; Coupier I; ; Hall J; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Carcinogenesis; 2017 Oct; 38(10):994-1003. PubMed ID: 28981872
[TBL] [Abstract][Full Text] [Related]
12. Population-based estimates of age-specific cumulative risk of breast cancer for pathogenic variants in ATM.
Renault AL; Dowty JG; Steen JA; Li S; Winship IM; Giles GG; Hopper JL; Southey MC; Nguyen-Dumont T
Breast Cancer Res; 2022 Apr; 24(1):24. PubMed ID: 35365198
[TBL] [Abstract][Full Text] [Related]
13. Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis.
Laitman Y; Nielsen SM; Bernstein-Molho R; Heald B; Hatchell KE; Esplin ED; Friedman E
Breast Cancer Res Treat; 2022 Nov; 196(2):355-361. PubMed ID: 36094610
[TBL] [Abstract][Full Text] [Related]
14. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.
Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J
Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508
[TBL] [Abstract][Full Text] [Related]
15. First international workshop of the ATM and cancer risk group (4-5 December 2019).
Lesueur F; Easton DF; Renault AL; Tavtigian SV; Bernstein JL; Kote-Jarai Z; Eeles RA; Plaseska-Karanfia D; Feliubadaló L; ; Arun B; Herold N; Versmold B; Schmutzler RK; ; Nguyen-Dumont T; Southey MC; Dorling L; Dunning AM; Ghiorzo P; Dalmasso BS; Cavaciuti E; Le Gal D; Roberts NJ; Dominguez-Valentin M; Rookus M; Taylor AMR; Goldstein AM; Goldgar DE; ; Stoppa-Lyonnet D; Andrieu N
Fam Cancer; 2022 Apr; 21(2):211-227. PubMed ID: 34125377
[TBL] [Abstract][Full Text] [Related]
16. Contribution of mutations in ATM to breast cancer development in the Czech population.
Soukupova J; Dundr P; Kleibl Z; Pohlreich P
Oncol Rep; 2008 Jun; 19(6):1505-10. PubMed ID: 18497957
[TBL] [Abstract][Full Text] [Related]
17. The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.
Weigelt B; Bi R; Kumar R; Blecua P; Mandelker DL; Geyer FC; Pareja F; James PA; ; Couch FJ; Eccles DM; Blows F; Pharoah P; Li A; Selenica P; Lim RS; Jayakumaran G; Waddell N; Shen R; Norton L; Wen HY; Powell SN; Riaz N; Robson ME; Reis-Filho JS; Chenevix-Trench G
J Natl Cancer Inst; 2018 Sep; 110(9):1030-1034. PubMed ID: 29506079
[TBL] [Abstract][Full Text] [Related]
18. Breast Irradiation Is Well Tolerated in Carriers of a Pathogenic ATM Variant.
Zureick AH; Zakalik D; Quinn TJ; Rangarajan TS; Grzywacz VP; Rotenbakh LR; Chen PY; Dilworth JT
Pract Radiat Oncol; 2024; 14(1):e29-e39. PubMed ID: 37742832
[TBL] [Abstract][Full Text] [Related]
19. Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk.
West AH; Blazer KR; Stoll J; Jones M; Weipert CM; Nielsen SM; Kupfer SS; Weitzel JN; Olopade OI
Fam Cancer; 2018 Oct; 17(4):495-505. PubMed ID: 29445900
[TBL] [Abstract][Full Text] [Related]
20. Penetrance of ATM Gene Mutations in Breast Cancer: A Meta-Analysis of Different Measures of Risk.
Marabelli M; Cheng SC; Parmigiani G
Genet Epidemiol; 2016 Jul; 40(5):425-31. PubMed ID: 27112364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
